Knight TherapeuticsFRA:04K +2.59%73 Pretax Margin % is 9.55% as of Mar. 2026, which is 1% above its 10-year median of 9.42. GuruFocus rates FRA:04K with a GF Score™ of 73/100 and a GF Value™ of €5.30. The stock has 6 warning signs investors should review. Among 953 Drug Manufacturers companies, Knight Therapeutics ranks worse than 64.32% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Knight Therapeutics Pretax Margin % Related Terms
Knight Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Knight Therapeutics (FRA:04K) has a Pretax Margin % of 9.55% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Knight Therapeutics and its competitors. This is near median its historical median of 9.42. According to the industry distribution chart, Knight Therapeutics ranks #613 out of 953 companies in the Drug Manufacturers industry, placing it in the top 64.3%.
Is Knight Therapeutics' Pretax Margin % too high?
Knight Therapeutics' current Pretax Margin % of 9.55% is near median its 10-year median of 9.42. The Drug Manufacturers industry median Pretax Margin % is 7.30. Knight Therapeutics' value of 9.55% is 30.8% above this industry median. Based on the distribution chart, Knight Therapeutics ranks #613 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Knight Therapeutics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #613 out of 953 companies for Pretax Margin %. This places Knight Therapeutics in the lower half of its industry. The industry median Pretax Margin % is 7.30. Knight Therapeutics' value of 9.55% is 30.8% above this benchmark. While the company's 10-year median is 9.42 vs. the industry median of 7.30, Knight Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current Pretax Margin % of 9.55% is 30.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current Pretax Margin % is 9.55%, which is near median its own 10-year median of 9.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current Pretax Margin % of 9.55%. The stock's GF Value™ is €5.30, compared to a current price of €5.95 — trading 12.3% above its estimated fair value. The current Pretax Margin % is 9.55%, which is near median its 10-year median of 9.42 and 30.8% above the Drug Manufacturers industry median of 7.30. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current Pretax Margin % is 9.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (FRA:04K) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of €5.95 is trading 12.3% above its estimated GF Value™ of €5.30.
Key valuation signals for FRA:04K:
Pretax Margin %: 9.55% (near median its 10-year median of 9.42)
GF Value™: €5.30 vs. price of €5.95 (12.3% above fair value)
Industry Position: 30.8% above the Drug Manufacturers median (#613 of 953)
No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score
Get the complete analysis for FRA:04K
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:04K has been successfully added to your 
